Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

1,009 results

• Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice: Complete Statistical AnalysisIndependent statistical analysis of Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 3,430NCT01793142
• Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration: Complete Statistical AnalysisIndependent statistical analysis of Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion,…Phase NAResults postedn = 1,502NCT03764631
• POSTOPIndependent statistical analysis of Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01377467).Phase 3Results postedn = 90NCT01377467
• PRACTICE-DMIndependent statistical analysis of Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 200NCT03520413
• Pramlintide in Adolescents With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Pramlintide in Adolescents With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00842075).Phase NAResults postedn = 10NCT00842075
• PRE-SURGE1Independent statistical analysis of PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00829829).Phase 3Results postedn = 241NCT00829829
• Precision Diets for Diabetes Prevention: Complete Statistical AnalysisIndependent statistical analysis of Precision Diets for Diabetes Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03919877).Phase NAResults postedn = 115NCT03919877
• Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals: Complete Statistical AnalysisIndependent statistical analysis of Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 100NCT01862796
• PREHABIndependent statistical analysis of A Supervised Prehabilitation Program for Patients With Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05692323).Phase NAResults postedn = 16NCT05692323
• PREVAIL-PIndependent statistical analysis of Exercise After Clinically Significant Weight Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685123).Phase NAResults postedn = 39NCT03685123
• PREVENTIndependent statistical analysis of Improving Patient Prioritization During Hospital-homecare Transition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04136951).Phase NAResults postedn = 1,915NCT04136951
• Preventing Diabetes in the Deep South: Extending Partnerships and Adapting Interventions to Reach Rural Communities at High Risk.: Complete Statistical AnalysisIndependent statistical analysis of Preventing Diabetes in the Deep South: Extending Partnerships and Adapting Interventions to Reach Rural Communities at High Risk.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 36NCT04343872
• Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Complete Statistical AnalysisIndependent statistical analysis of Prevention of Bone Loss After Acute SCI by Zoledronic Acid: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02325414).Phase 2Results postedn = 60NCT02325414
• Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02074631).Phase 2Results postedn = 63NCT02074631
• PRO SoloIndependent statistical analysis of Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03478969).Phase NAResults postedn = 181NCT03478969
• Project Impact: An Innovative Approach to Weight Loss Maintenance: Complete Statistical AnalysisIndependent statistical analysis of Project Impact: An Innovative Approach to Weight Loss Maintenance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02363010).Phase NAResults postedn = 320NCT02363010
• PROLONG-ANG3Independent statistical analysis of A Study of LY3561774 in Participants With Mixed Dyslipidemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05256654).Phase 2Results postedn = 205NCT05256654
• PROMINENTIndependent statistical analysis of Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 10,544NCT03071692
• PROMISEIndependent statistical analysis of Endoscopic Suturing for Primary Obesity Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01662024).Phase NAResults postedn = 20NCT01662024
• PROMISEIndependent statistical analysis of Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 30NCT01988246
• Promoting Physical Growth and Positive Development in Severely Stunted Guatemalan Children: Complete Statistical AnalysisIndependent statistical analysis of Promoting Physical Growth and Positive Development in Severely Stunted Guatemalan Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 324NCT02509936
• Promoting Resilience to Food Commercials Decreases Susceptibility to Unhealthy Food Decision-Making: Complete Statistical AnalysisIndependent statistical analysis of Promoting Resilience to Food Commercials Decreases Susceptibility to Unhealthy Food Decision-Making: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 49NCT04905498
• PRONTO-PumpIndependent statistical analysis of A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes: primary endpoint results, effect estimate with…Phase 3Results postedn = 49NCT03433677
• PRONTO-T1DA detailed statistical analysis of the randomized phase 3 PRONTO-T1D trial of LY900014 in participants with type 1 diabetes, including HbA1c, postprandial glucose, non-inferiority, ANCOVA, mixed-effects modeling, and safety.Phase 3Results postedn = 1,392NCT03214367
• PRONTO-T2DIndependent statistical analysis of A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 933NCT03214380
• Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 42NCT00727220
• Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 254NCT00920582
• Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study: Complete Statistical AnalysisIndependent statistical analysis of Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00604383).Phase 3Results postedn = 685NCT00604383
• PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria: Complete Statistical AnalysisIndependent statistical analysis of PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 34NCT03168295
• Protocol1Independent statistical analysis of Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03560323).Phase 1Results postedn = 41NCT03560323
• Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 34NCT00245050
• QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.: Complete Statistical AnalysisIndependent statistical analysis of QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 154NCT05553912
• Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00845130).Phase NAResults postedn = 42NCT00845130
• Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia: Complete Statistical AnalysisIndependent statistical analysis of Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 48NCT03476330
• QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer: Complete Statistical AnalysisIndependent statistical analysis of QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 3NCT03127098
• Randomized Study of Daytime vs. Delayed Eating: Effect on Weight and Metabolism: Complete Statistical AnalysisIndependent statistical analysis of Randomized Study of Daytime vs. Delayed Eating: Effect on Weight and Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 17NCT04414644
• Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 948NCT01565564
• Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop: Complete Statistical AnalysisIndependent statistical analysis of Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02328040).Phase 1Results postedn = 17NCT02328040
• RDVCGHIndependent statistical analysis of Racial Differences in Vagal Control of Glucose Homeostasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02365285).Phase 1/2Results postedn = 23NCT02365285
• Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436: Complete Statistical AnalysisIndependent statistical analysis of Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534897).Phase NAResults postedn = 10NCT01534897
• Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients: Complete Statistical AnalysisIndependent statistical analysis of Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00675103).Phase 3Results postedn = 7NCT00675103
• Real World Glycemic Effectiveness of Linagliptin: Complete Statistical AnalysisIndependent statistical analysis of Real World Glycemic Effectiveness of Linagliptin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03338803).Phase NAResults postedn = 11,001NCT03338803
• REALYSEIndependent statistical analysis of A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE): primary endpoint results, effect estimate with confidence…Phase 4Results postedn = 1,018NCT05035082
• RECORDComplete statistical analysis of the RECORD phase 3 trial of rosiglitazone and cardiovascular outcomes in type 2 diabetes, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, non-inferiority analysis, re-adjudication outcomes, safety,…Phase 3Results postedn = 4,447NCT00379769
• Reduction in the Occurrence of Center-Involved Diabetic Macular Edema: Complete Statistical AnalysisIndependent statistical analysis of Reduction in the Occurrence of Center-Involved Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00090519).Phase 3Results postedn = 731NCT00090519
• Regulatory Request NIS in Korea: Complete Statistical AnalysisIndependent statistical analysis of Regulatory Request NIS in Korea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03642717).Phase NAResults postedn = 658NCT03642717
• Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness: Complete Statistical AnalysisIndependent statistical analysis of Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 303NCT00229957
• RELIEFIndependent statistical analysis of LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 30NCT02429830
• REMIT-DMIndependent statistical analysis of Remission Through Early Monitored Insulin Therapy - Duration Month: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03670641).Phase 4Results postedn = 10NCT03670641
• REMOVALIndependent statistical analysis of REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 493NCT01483560

← All therapeutic areas